Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England.
Serological responses and vaccine effectiveness for extended COVID-19 vaccine schedules in England.
复制标题
DOI：
10.1038/s41467-021-27410-5
复制
发表时间：
2021-12-10
影响因子：
16.6
通讯作者：
Ramsay ME
中科院分区：
文献类型：
--
作者：
Amirthalingam G;Bernal JL;Andrews NJ;Whitaker H;Gower C;Stowe J;Tessier E;Subbarao S;Ireland G;Baawuah F;Linley E;Warrener L;O'Brien M;Whillock C;Moss P;Ladhani SN;Brown KE;Ramsay ME
英国优先交付第一剂BNT 162 b2（辉瑞/BioNTech）和AZD 1222（阿斯利康）疫苗，将接种间隔延长至12周。在750名年龄在50-89岁之间的参与者中，我们比较了不同剂量间隔的BNT 162 b2和AZD 1222疫苗接种后的血清学应答，并根据英格兰实际国家疫苗有效性（VE）估计值对这些结果进行评估。我们发现，在接种间隔延长的BNT 162 b2接种者中，第二剂接种后14-35天的抗体水平较高（65-84天），与标准间隔（19-29天）接种疫苗相比。在延长的时间表后，第2次给药后14-35天，BNT 162 b2的抗体水平是AZD 1222的6倍。对于这两种疫苗，与一剂疫苗相比，从第二剂疫苗接种后14天起，所有年龄组的VE均较高，但幅度随接种间隔而变化。与标准时间表相比，在BNT 162 b2剂量之间间隔>6周的情况下观察到更高剂量的两次VE。鉴于全球疫苗的限制，这些结果对政策制定者具有重要意义。英国将第二剂COVID-19疫苗接种的间隔延长至12周。在这里，作者在750名年龄在50-89岁之间的参与者中显示，延长的时间表导致更高的抗体滴度，并估计延长时间表的疫苗有效性更高。
The UK prioritised delivery of the first dose of BNT162b2 (Pfizer/BioNTech) and AZD1222 (AstraZeneca) vaccines by extending the interval between doses up to 12 weeks. In 750 participants aged 50–89 years, we here compare serological responses after BNT162b2 and AZD1222 vaccination with varying dose intervals, and evaluate these against real-world national vaccine effectiveness (VE) estimates against COVID-19 in England. We show that antibody levels 14–35 days after dose two are higher in BNT162b2 recipients with an extended vaccine interval (65–84 days) compared with those vaccinated with a standard (19–29 days) interval. Following the extended schedule, antibody levels were 6-fold higher at 14–35 days post dose 2 for BNT162b2 than AZD1222. For both vaccines, VE was higher across all age-groups from 14 days after dose two compared to one dose, but the magnitude varied with dose interval. Higher dose two VE was observed with >6 week interval between BNT162b2 doses compared to the standard schedule. Our findings suggest higher effectiveness against infection using an extended vaccine schedule. Given global vaccine constraints these results are relevant to policymakers. The UK extended the interval until the second COVID-19 vaccine dose up to 12 weeks. Here, the authors show in a cohort of 750 participants aged 50–89 years that the extended schedule results in higher antibody titers and estimate a higher vaccine effectiveness for the extended schedule.
登录
查看更多内容
BNT162B2 mRNA COVID-19疫苗的安全性和功效。
DOI：
10.1056/nejmoa2034577
发表时间：
2020-12-31
期刊：
The New England journal of medicine
影响因子：
--
作者：
Polack FP;Thomas SJ;Kitchin N;Absalon J;Gurtman A;Lockhart S;Perez JL;Pérez Marc G;Moreira ED;Zerbini C;Bailey R;Swanson KA;Roychoudhury S;Koury K;Li P;Kalina WV;Cooper D;Frenck RW Jr;Hammitt LL;Türeci Ö;Nell H;Schaefer A;Ünal S;Tresnan DB;Mather S;Dormitzer PR;Şahin U;Jansen KU;Gruber WC;C4591001 Clinical Trial Group
通讯作者：
C4591001 Clinical Trial Group
DOI：
10.1016/s0140-6736(21)00432-3
发表时间：
2021-03-06
期刊：
Lancet (London, England)
影响因子：
--
作者：
Voysey M;Costa Clemens SA;Madhi SA;Weckx LY;Folegatti PM;Aley PK;Angus B;Baillie VL;Barnabas SL;Bhorat QE;Bibi S;Briner C;Cicconi P;Clutterbuck EA;Collins AM;Cutland CL;Darton TC;Dheda K;Dold C;Duncan CJA;Emary KRW;Ewer KJ;Flaxman A;Fairlie L;Faust SN;Feng S;Ferreira DM;Finn A;Galiza E;Goodman AL;Green CM;Green CA;Greenland M;Hill C;Hill HC;Hirsch I;Izu A;Jenkin D;Joe CCD;Kerridge S;Koen A;Kwatra G;Lazarus R;Libri V;Lillie PJ;Marchevsky NG;Marshall RP;Mendes AVA;Milan EP;Minassian AM;McGregor A;Mujadidi YF;Nana A;Padayachee SD;Phillips DJ;Pittella A;Plested E;Pollock KM;Ramasamy MN;Ritchie AJ;Robinson H;Schwarzbold AV;Smith A;Song R;Snape MD;Sprinz E;Sutherland RK;Thomson EC;Török ME;Toshner M;Turner DPJ;Vekemans J;Villafana TL;White T;Williams CJ;Douglas AD;Hill AVS;Lambe T;Gilbert SC;Pollard AJ;Oxford COVID Vaccine Trial Group
通讯作者：
Oxford COVID Vaccine Trial Group
影响因子：
2.7
作者：
Jung K;Shin S;Nam M;Hong YJ;Roh EY;Park KU;Song EY
通讯作者：
Song EY
影响因子：
64.8
作者：
Collier DA;Ferreira IATM;Kotagiri P;Datir RP;Lim EY;Touizer E;Meng B;Abdullahi A;CITIID-NIHR BioResource COVID-19 Collaboration;Elmer A;Kingston N;Graves B;Le Gresley E;Caputo D;Bergamaschi L;Smith KGC;Bradley JR;Ceron-Gutierrez L;Cortes-Acevedo P;Barcenas-Morales G;Linterman MA;McCoy LE;Davis C;Thomson E;Lyons PA;McKinney E;Doffinger R;Wills M;Gupta RK
通讯作者：
Gupta RK
DOI：
10.1056/nejmoa2108891
发表时间：
2021-08-12
期刊：
The New England journal of medicine
影响因子：
--
作者：
Lopez Bernal J;Andrews N;Gower C;Gallagher E;Simmons R;Thelwall S;Stowe J;Tessier E;Groves N;Dabrera G;Myers R;Campbell CNJ;Amirthalingam G;Edmunds M;Zambon M;Brown KE;Hopkins S;Chand M;Ramsay M
通讯作者：
Ramsay M